Based on the Amicus Therapeutics Inc stock forecast from 9 analysts, the average analyst target price for Amicus Therapeutics Inc is USD 17.00 over the next 12 months. Amicus Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Amicus Therapeutics Inc is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, Amicus Therapeutics Inc’s stock price was USD 6.90. Amicus Therapeutics Inc’s stock price has changed by +2.68% over the past week, -22.47% over the past month and -35.27% over the last year.
No recent analyst target price found for Amicus Therapeutics Inc
No recent average analyst rating found for Amicus Therapeutics Inc
Company Overview Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. Read Less
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered m...Read More
Frequently Asked Questions About Amicus Therapeutics Inc (FOLD) Stock
Based on ratings from 9 analysts Amicus Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 10 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on FOLD's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for FOLD is USD 17.00 over the next 12 months. The maximum analyst target price is USD 21 while the minimum anlayst target price is USD 12.
Unfortunately we do not have enough data on FOLD's stock to indicate if its overvalued.
The last closing price of FOLD's stock was USD 6.90.
The most recent market capitalization for FOLD is USD 2.79B.
Based on targets from 9 analysts, the average taret price for FOLD is projected at USD 17.00 over the next 12 months.
This means that FOLD's stock price may go up by +146.38% over the next 12 months.
We can't find any ETFs which contains Amicus Therapeutics Inc's stock.
As per our most recent records Amicus Therapeutics Inc has 499 Employees.
Amicus Therapeutics Inc's registered address is 47 Hulfish Street, Princeton, NJ, United States, 08542.
You can get more information about it from Amicus Therapeutics Inc's website at https://amicusrx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Amicus Therapeutics Inc (FOLD) Stock
Based on ratings from 9 analysts Amicus Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 10 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on FOLD's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for FOLD is USD 17.00 over the next 12 months. The maximum analyst target price is USD 21 while the minimum anlayst target price is USD 12.
Unfortunately we do not have enough data on FOLD's stock to indicate if its overvalued.
The last closing price of FOLD's stock was USD 6.90.
The most recent market capitalization for FOLD is USD 2.79B.
Based on targets from 9 analysts, the average taret price for FOLD is projected at USD 17.00 over the next 12 months.
This means that FOLD's stock price may go up by +146.38% over the next 12 months.
We can't find any ETFs which contains Amicus Therapeutics Inc's stock.
As per our most recent records Amicus Therapeutics Inc has 499 Employees.
Amicus Therapeutics Inc's registered address is 47 Hulfish Street, Princeton, NJ, United States, 08542.
You can get more information about it from Amicus Therapeutics Inc's website at https://amicusrx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for FOLD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
